Loading
Latest filing published 28 Mar 2024 for NervGen Pharma Corp., €70k.
William James Adams discloses dealings in NervGen Pharma Corp. to SEDI. We count 6 filings; the first trade dates from 21 February 2020 and the latest from 28 March 2024.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
On 28 March 2024 came the latest disclosure, a transaction for €70k in NervGen Pharma Corp. Between a trade and the moment it shows up on SEDI, the median delay is 2 days. Until a filing is published, the market cannot know about the trade. This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations